
HUTCHMED (China) Limited – NASDAQ:HCM
HUTCHMED (China) Limited stock price today
HUTCHMED (China) Limited stock price monthly change
HUTCHMED (China) Limited stock price quarterly change
HUTCHMED (China) Limited stock price yearly change
HUTCHMED (China) Limited key metrics
Market Cap | 2.46B |
Enterprise value | 1.95B |
P/E | -6.13 |
EV/Sales | 7.14 |
EV/EBITDA | -11.59 |
Price/Sales | 8.20 |
Price/Book | 3.67 |
PEG ratio | 0.08 |
EPS | 0.65 |
Revenue | 1.26B |
EBITDA | 37.95M |
Income | 149.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -63.69% |
Oper. margin | -91.03% |
Gross margin | 1.74% |
EBIT margin | -91.03% |
EBITDA margin | 3% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHUTCHMED (China) Limited stock price history
HUTCHMED (China) Limited stock forecast
HUTCHMED (China) Limited financial statements
Mar 2023 | 266.43M | 84.27M | 31.63% |
---|---|---|---|
Jun 2023 | 532.87M | 168.55M | 31.63% |
Sep 2023 | 152.56M | -33.88M | -22.21% |
Dec 2023 | 311.70M | -69.23M | -22.21% |
Sep 2025 | 80.92M | -305.20M | -377.15% |
---|---|---|---|
Dec 2025 | 90.66M | -288.14M | -317.82% |
Mar 2026 | 175.22M | -869.42M | -496.19% |
Jun 2026 | 210.04M | -1.04B | -497.13% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 0% |
---|
2019 | |
---|---|
2020 | |
2021 | 0.36% |
2022 | 0.7% |
2023 |
Feb 2023 | 1297497000 | 497.48M | 38.34% |
---|---|---|---|
Jun 2023 | 1297497000 | 497.48M | 38.34% |
Sep 2023 | 1279773000 | 536.38M | 41.91% |
Dec 2023 | 1279773000 | 536.38M | 41.91% |
Mar 2023 | 113.20M | -157.97M | 2.91M |
---|---|---|---|
Jun 2023 | 250.25M | -339.81M | 5.83M |
Sep 2023 | -3.57M | 12.41M | 21.41M |
Dec 2023 | -26.27M | 42.39M | 43.87M |
HUTCHMED (China) Limited alternative data
Aug 2023 | 1,280 |
---|---|
Sep 2023 | 1,990 |
Oct 2023 | 1,990 |
Nov 2023 | 1,990 |
Dec 2023 | 1,990 |
Jan 2024 | 1,990 |
Feb 2024 | 1,990 |
Mar 2024 | 1,988 |
Apr 2024 | 1,988 |
May 2024 | 1,988 |
Jun 2024 | 1,988 |
Jul 2024 | 1,988 |
HUTCHMED (China) Limited other data
Quarter | Transcript |
---|---|
Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
Q4 2022 28 Feb 2023 | Q4 2022 Earnings Call Transcript |
Q2 2022 3 Aug 2022 | Q2 2022 Earnings Call Transcript |
Q4 2021 3 Mar 2022 | Q4 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Christian Hogg B.Sc., BSc, M.B.A., MBA (1966) Chief Executive Officer & Executive Director | $1,410,000 |
Dr. Weiguo Su B.Sc., Ph.D. (1957) Chief Scientific Officer, Executive Vice President & Executive Director | $1,210,000 |
Mr. Johnny Cheng C.A., BEc, CA (1967) Chief Financial Officer & Executive Director | $788,960 |
Mr. Chi Keung To ACGI, B.Sc., M.B.A. (1952) Executive Chairman | $80,000 |
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito (1952) Company Sec. & Non-Executive Director | $70,000 |
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
HUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drug
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
Hutchmed: Attractive Chinese R&D Giant
Week In Review: Suzhou Duality Out-Licenses 2 ADCs To BioNTech In $1.7 Billion Deal
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Paycor HCM: A Product That Fits The HCM Needs Of SMEs Today
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Alibaba And Chinese Tech Stocks: Come Out Of Hiding Now - It's Time To Buy
-
What's the price of HUTCHMED (China) Limited stock today?
One share of HUTCHMED (China) Limited stock can currently be purchased for approximately $16.21.
-
When is HUTCHMED (China) Limited's next earnings date?
Unfortunately, HUTCHMED (China) Limited's (HCM) next earnings date is currently unknown.
-
Does HUTCHMED (China) Limited pay dividends?
No, HUTCHMED (China) Limited does not pay dividends.
-
How much money does HUTCHMED (China) Limited make?
HUTCHMED (China) Limited has a market capitalization of 2.46B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 96.52% to 838M US dollars.
-
What is HUTCHMED (China) Limited's stock symbol?
HUTCHMED (China) Limited is traded on the NASDAQ under the ticker symbol "HCM".
-
What is HUTCHMED (China) Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of HUTCHMED (China) Limited?
Shares of HUTCHMED (China) Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are HUTCHMED (China) Limited's key executives?
HUTCHMED (China) Limited's management team includes the following people:
- Mr. Christian Hogg B.Sc., BSc, M.B.A., MBA Chief Executive Officer & Executive Director(age: 59, pay: $1,410,000)
- Dr. Weiguo Su B.Sc., Ph.D. Chief Scientific Officer, Executive Vice President & Executive Director(age: 68, pay: $1,210,000)
- Mr. Johnny Cheng C.A., BEc, CA Chief Financial Officer & Executive Director(age: 58, pay: $788,960)
- Mr. Chi Keung To ACGI, B.Sc., M.B.A. Executive Chairman(age: 73, pay: $80,000)
- Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito Company Sec. & Non-Executive Director(age: 73, pay: $70,000)
-
How many employees does HUTCHMED (China) Limited have?
As Jul 2024, HUTCHMED (China) Limited employs 1,988 workers.
-
When HUTCHMED (China) Limited went public?
HUTCHMED (China) Limited is publicly traded company for more then 9 years since IPO on 16 Mar 2016.
-
What is HUTCHMED (China) Limited's official website?
The official website for HUTCHMED (China) Limited is hutch-med.com.
-
How can i contact HUTCHMED (China) Limited?
HUTCHMED (China) Limited can be reached via phone at +852 2128 1188.
HUTCHMED (China) Limited company profile:

HUTCHMED (China) Limited
hutch-med.comNASDAQ
1,970
Drug Manufacturers - Specialty & Generic
Healthcare
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Central,
CIK: 0001648257
ISIN: US44842L1035
CUSIP: 44842L103